Positive outcomes with an experimental vaccine provide hope for patients with stage IIB and IIC melanoma.
Though still considered controversial, several evolving treatment and management plans for primary cutaneous melanoma are making their way into the mainstream and challenging more traditional approaches.
Novartis, Quest Diagnostics collaborate on free genetic mutation testing initiative, The Know Now BRAF program, for patients with stage III or stage IV melanoma.
There are many different aspects to the treatment and management of primary melanoma, but clinicians differ on their perceptions of the ideal treatment approach.
As age is the strongest risk factor in NMSC, dermatologists can see an increase in this type of cancer in elderly patients, and treatment preferences vary.
Melanoma located on the head and neck are associated with a potentially worse prognosis relative to alternate anatomical sites and peripherally located melanoma compared to those centrally located.
Accurately diagnosing some melanocytic neoplasms is challenging because they may fall into a grey area histologically, one expert says. Recent progress in molecular genetics can help dermatopathologists more precisely classify tumors, leading to more appropriate treatment and management choices.
Dermatologists should work to gain a better understanding of immunologic pathways as well as the mechanisms of new and evolving immunotherapies, as these are key for understanding many current and emerging melanoma treatments, one expert says.
Innovative melanoma therapeutics are on the horizon. This pipeline report highlights some of the new drugs currently in phase 2, phase 3 or recently approved for the treatment of melanoma.
Sentinel lymph node biopsy (SLNB) has classically been performed for regional disease control and to hopefully prevent disease metastasis; however, according to this expert, there has not been any good evidence to support this practice.